1、Novo Nordisk A/S Novo Alle 1,2880 Bagsvrd,Denmark CVR no.24256790A Novo Nordisk employee receiving a tour of our active construction project at our site in Kalundborg,Denmark.This project is part of our investment of more than DKK 80 billion in new active pharmaceutical ingredient facilities.These s

2、ignificant expansions aim to scale up production of life-changing treatments,including GLP-1-based medicines,to benefit many more people living with serious chronic diseases.REMUNERATIONREPORT2024Remuneration Report 2024 2Contents 1.Letter from the Remuneration Committee Chair 3 2.Remuneration of th

3、e Board of Directors2.1 Key developments in Board remuneration in 2024 42.2 Remuneration composition 42.3 Board remuneration benchmark 62.4 Board and committee fee levels 2024 62.5 Board remuneration 2024 72.6 Shareholdings of Board Members 73.Remuneration of Executive Management 3.1 Key development

4、s in executive remuneration 2024 83.2 Remuneration composition 83.3 Executive remuneration benchmark 113.4 Executive remuneration in 2024 123.5 Short-term incentive programme 2024 133.6 Long-term incentive programme design 163.7 Long-term incentive programme 2022 173.8 Long-term incentive programmes

5、 2023 and 2024 183.9 Shareholdings of Executive Management 193.10 Reconciliation against Annual Report 2024 204.Remuneration and Company Performance 202020244.1 Board remuneration 20202024 214.2 Executive remuneration 20202024 224.3 Employee remuneration and company performance 20202024 23The Board

6、of Directors statement on the Remuneration Report 24Independent auditors statement on the Remuneration Report 25This Remuneration Report describes the remuneration received by each member of the Board of Directors and Executive Management of Novo Nordisk A/S as registered with the Danish Business Au